Published on 29 May 2024 on Zacks via Yahoo Finance
Reasons to Retain PacBio (PACB) Stock in Your Portfolio
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism, led by a decent first-quarter 2024 performance and its product development activities, is expected to contribute further. However, stiff competition and macroeconomic concerns persist.
In the year-to-date period, this Zacks Rank #3 (Hold) stock has lost 80.9% against 6.9% growth of the industry. The S&P 500 Composite also gained 11.6% in the same time frame.